Quick Order

CD80 / B7-1 Antibody (FITC), Mouse MAb

DatasheetSpecific PreferencesReviewsResearch TopicsProtocols
B7-1/CD80Antibody Product Information
Antigen:Recombinant Human CD80 / B7-1 Protein (Catalog#10698-H08H)
Clone ID:01
Ig Type:Mouse IgG1
Concentration:10 μl/Test, 0.1 mg/ml
Formulation:Aqueous solution containing 0.5% BSA and 0.09% sodium azide
Preparation:This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD80 / B7-1 (rh CD80 / B7-1; Catalog#10698-H08H; NP_005182.1; Met 1-Asn 242) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.
B7-1/CD80Antibody Usage Guide
Specificity:Human CD80 / B7-1
Application:FCM
Storage:This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.
Images
CD80 / B7-1 Antibody (FITC), Mouse MAb, Flow cytometric
View larger image
Caption:
Profile of anti-B7-1 (CD80) reactivity on U937 cells analyzed by flow cytometry. Cells should be Fc-blocked by treatment with 20 μg of human IgG/106 cells for 1 hour at 4 ℃ prior to staining, washed, then stained with FITC Mouse anti-B7-1 (CD80).

The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Reference
  • Greenfield EA, et al. (1998) CD28/B7 costimulation: a review. Crit Rev Immunol. 18(5): 389-418.
  • Zang X, et al. (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 13(18 Pt 1): 5271-9.
  • Mir MA, et al. (2008) Signaling through CD80: an approach for treating lymphomas. Expert Opin Ther Targets. 12(8): 969-79.
  • Related Products
    Product nameProduct name
    Size / Price
    Catalog:10698-MM01-F-50
    List Price: $130.00  (Save $0.00)
    Price:$130.00      [How to order]
    Availsability:In Stock
    Images
    • CD80 / B7-1 Antibody (FITC), Mouse MAb, Flow cytometric
    Please note:All products are "FOR RESEARCH UES ONLY AND ARE NOT INTENDED FOR DIAGNOSTICE OFR THERAPEUTIC USE"